Proton-pump inhibitor use and the risk for community-acquired pneumonia

被引:207
|
作者
Sarkar, Monika [1 ]
Hennessy, Sean [1 ]
Yang, Yu-Xiao [1 ]
机构
[1] Univ Penn, Ctr Clin Epidemiol & Biostat, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.7326/0003-4819-149-6-200809160-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP). Objective: To examine the association between PPI use and CAP in adults followed in general practices in the United Kingdom. Design: Nested case-control study. Setting: The General Practice Research Database (1987 to 2002) in the United Kingdom. Participants: Patients age 18 years or older with at least 6 months of initial pneumonia-free follow-up in the database. Case patients (n = 80 066) were defined as those who received an incident diagnosis of CAP. Control participants (n = 799 881) were selected by using incidence density sampling, matching on practice site, calendar period, and follow-up duration. Measurements: Use of PPIs within 30 days before the index date. Adjusted odds ratios (ORs) were estimated by using conditional logistic regression, adjusting for potential confounders. Results: Overall, current PPI use was not associated with an increased risk for CAP (adjusted OR, 1.02 [95% CI, 0.97 to 1.08]) or risk for CAP that required hospitalization (adjusted OR, 1.01 [CI, 0.91 to 1.12]). There was a strong increase in risk for CAP associated with current use of PPI therapy that was started within the previous 2 days (adjusted OR, 6.53 [CI, 3.95 to 10.80]), 7 days (adjusted OR, 3.79 [CI, 2.66 to 5.42]), and 14 days (adjusted OR, 3.21 [CI, 2.46 to 4.18]), but there was no statistically significant association for longer-term current PPI therapy. A separate matched case-control analysis, which included the 3 strongest confounders as additional matching factors, yielded similar results as the primary analysis (adjusted OR, 0.96 [CI, 0.91 to 1.02]). Limitations: Adherence to PPI prescription was assumed to be 100%. No radiographic evidence was available to corroborate a diagnosis of CAP. Conclusion: Proton-pump inhibitor therapy started within the past 30 days was associated with an increased risk for CAP, whereas longer-term current use was not.
引用
收藏
页码:391 / W75
页数:10
相关论文
共 50 条
  • [31] Tetany secondary to the use of a proton-pump inhibitor
    Subbiah, V
    Tayek, JA
    ANNALS OF INTERNAL MEDICINE, 2002, 137 (03) : 218 - 219
  • [32] Tetany Secondary to the Use of a Proton-Pump Inhibitor
    Patel, Hiren
    Depasquale, Joseph
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S1125 - S1126
  • [33] Proton pump inhibitor use is associated with an increased risk of severe community acquired infections
    Targownik, Laura E.
    Laheij, Robert J.
    Metge, Colleen
    Leung, Stella
    GASTROENTEROLOGY, 2007, 132 (04) : A159 - A159
  • [34] THE USE OF DISTRIBUTED-PROTOCOL PROSPECTIVE META-ANALYSIS OF OBSERVATIONAL STUDIES TO ASSESS ADVERSE DRUG EFFECTS: PROTON-PUMP INHIBITORS AND THE RISK OF HOSPITALIZATION FOR COMMUNITY-ACQUIRED PNEUMONIA.
    Filion, K. B.
    Chateau, D.
    Dormuth, C. R.
    Gershon, A.
    Targownik, L. E.
    Durand, M.
    Tamim, H.
    Teare, G. F.
    Ravani, P.
    Ernst, P.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 : S144 - S144
  • [35] Microbial evaluation of proton-pump inhibitors and the risk of pneumonia
    Meijvis, S. C. A.
    Cornips, M. C. A.
    Voorn, G. P.
    Souverein, P. C.
    Endeman, H.
    Biesma, D. H.
    Leufkens, H. G. M.
    van de Garde, M. W.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (05) : 1165 - 1172
  • [36] THE USE OF DISTRIBUTED-PROTOCOL PROSPECTIVE META-ANALYSIS OF OBSERVATIONAL STUDIES TO ASSESS ADVERSE DRUG EFFECTS: PROTON-PUMP INHIBITORS AND THE RISK OF HOSPITALIZATION FOR COMMUNITY-ACQUIRED PNEUMONIA.
    Filion, K. B.
    Chateau, D.
    Dormuth, C. R.
    Gershon, A.
    Targownik, L. E.
    Durand, M.
    Tamim, H.
    Teare, G. F.
    Ravani, P.
    Ernst, P.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 : S142 - S142
  • [37] Use of proton pump inhibitors and the risk of community acquired pneumonia: A Populationbased case control study
    Gulmez, Sinem Ezgi
    Holm, Anette
    Frederiksen, Henrik
    Jensen, Thoger Gorm
    Pedersen, Court
    Hallas, Jesper
    EURASIAN JOURNAL OF PULMONOLOGY, 2008, 10 (03) : 177 - 183
  • [38] Proton pump inhibitors and community acquired pneumonia
    Filion, Kristian B.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 355
  • [39] Use of ACE inhibitors and risk of community-acquired pneumonia: a review
    Rafailidis, Petros I.
    Matthaiou, Dimitrios K.
    Varbobitis, Ioannis
    Falagas, Matthew E.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (06) : 565 - 573
  • [40] Pharmacotherapy and the risk for community-acquired pneumonia
    Gau, Jen-Tzer
    Acharya, Utkarsh
    Khan, Salman
    Heh, Victor
    Mody, Lona
    Kao, Tzu-Cheg
    BMC GERIATRICS, 2010, 10